Vesicor Therapeutics, Inc.

Warren Hosseinion, MD

Chairman of the Board

Dr. Hosseinion has served as the Chairman of our board since February 2023. Dr. Hosseinion is a co-founder of Apollo Medical Holdings, Inc. (NASDAQ: AMEH), was a member of its board of directors from July 2008 to March 2019 and served as its Chief Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of directors of Clinigence Holdings, Inc. from April 2019 to March 2022, Chief Executive Officer of Clinigence Holdings, Inc. from March 2021 to March 2022, and following a business combination with Nutex Health, Inc. he continues to be a director and President of Nutex Health, Inc. (NASDAQ: NUTX) from April 2022 to present. Dr. Hosseinion has also served as Chairman of the Board of Cardio Diagnostics, Inc. (NASDAQ: CDIO) from May 2022 to present. He has also served as Chairman of the Board of Altitude Acquisition Corporation (NASDAQ: ALTU) from September 2022 until present. In 2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in physiology and biophysics from the Georgetown University Graduate School of Arts and Sciences and his medical degree from the Georgetown University School of Medicine. He completed his internship and residency in internal medicine at the University of Southern California Medical Center.

Oded Levy

Director

Mr. Levy has served as a member of the Company’s Board of Directors since February 2023. He is the founder, president and managing partner of Blue Ox Healthcare Partners, ("Blue Ox”) a private equity firm based in New York City that invests growth capital in commercial-stage healthcare companies, with a focus on companies involved in precision health. Mr. Levy has over 30 years of experience in specialized healthcare investing in private equity, capital markets and asset management. He co-founded Blue Ox in 2009, leads origination and structuring of the firm’s investments, and chairs the Investment Committee. Mr. Levy is also a Board Director of Cardio Diagnostics, Inc. (NASDAQ: CDIO). Prior to Blue Ox, he was a principal at Oracle Partners, LP, a private investment firm specializing in public securities investing and merchant banking in the healthcare, bioscience and related industries. Previously, he was Head Trader and a member of the Executive Committee at Genesis Merchant Group Securities, a San Francisco-based investment bank. Mr. Levy was also Senior Vice President of Investments at Bering Holdings, Inc., the investment arm of publicly traded MAXXAM, Inc. He began his career in 1987 as a corporate finance analyst at Bear, Stearns & Co. Inc. Mr. Levy previously served on the boards of former Blue Ox investments, MedSave USA, as Executive Chairman, Delphi Behavioral Health Group and Infinity Funding. He holds an MBA in Finance and International Business and a BS in Computer and Information Systems from New York University.

Luo Feng, PhD

Founder, Chief Executive Officer and Director

Dr. Feng is the Founder and Chief Executive Officer of Vesicor Therapeutics, Inc. Dr. Feng has over 30 years’ experience as a research scientist in cell and molecular biology. He has a strong background in studies of the cell cycle, DNA replication, regulation of gene expression, gene transfer with recombinant retrovirus, DNA-protein interactions, expertise in cloning, cell type-specific gene expression and gene transfection and transduction in mammalian systems. Dr. Feng has conducted research at the National Laboratory of Molecular Oncology at the Chinese Academy of Medical Sciences (CAMS) in Beijing, at the Saban Institute at Childrens Hospital of Los Angeles, at UCLA, and the Beckman Research Institute at City of Hope National Medical Center. In 2008, Dr. Feng founded RNTein Biotech Lab with the goal of commercializing microvesicle-based therapeutics. He has published extensively in multiple scientific journals. Dr. Feng has a BS degree in medical sciences from Anhui Medical College (Hefei, Anhui, China), a M.S. degree in biochemistry from the Cancer Institute of the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) in Beijing, and a Ph.D. in molecular biology from CAMS and PUMC. He was a postdoctoral fellow in the Department of Hematology and Oncology at Childrens Hospital of Los Angeles and completed further postdoctoral research in the Department of Molecular and Medical Pharmacology at UCLA.